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ABSTRACT 
Celiac disease is an autoimmune disease that causes damage to the small intestine as a 
result of ingesting gluten. Approximately 1% of the U.S population has it, but individuals 
have a higher chance of getting the disease if they have the DQ2 gene or certain health 
problems. The ingestion of gluten or being on a gluten free diet can also cause additional 
health problems in the individual because they do not get enough vitamins and nutrients. 
Since a gluten free diet is not always effective, other treatments options are currently 
being researched including immunotherapy and modified wheat. This review will focus 
on genetic and health susceptibility factors in order to diagnose individuals sooner and 
to find more effective treatments. The implication of this new data can increase the 
quality of life in those affected by the disease.   
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INTRODUCTION 
Celiac disease (CD) is an autoimmune disease characterized by an immune response to 
gluten in the small intestine.(1) CD is prevalent in 0.5-1% of the population.(1) It is 
associated with an individual’s genetic makeup(1) and specific health problems they may 
have.(2) Certain individuals are more likely to develop celiac disease due to genetic 
variation in the major histocompatibility complex (MHC) region.(3) However, this known 
genetic influence is not enough to explain disease development.(3-5) Individuals with 
celiac disease have an increased risk of reproductive abnormalities, impaired bone 
health, cardiovascular and autoimmune diseases, and lymphoproliferative disorders 
even if they follow a strict gluten free diet (GFD), the only known effective treatment for 
CD.(2)  
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Gluten is a protein found in wheat, barely, and rye which are most often found in bread, 
pasta, baked goods and certain alcohols such as beer. In addition, it can be found in 
toothpastes, lip balms, hair and skin products, medicines, and supplements.  Therefore, 
following a GFD can be challenging, but it allows recovery of the small intestine, 
specifically the villi, which absorbs nutrients. Because of this recovery, a GFD also helps 
lessen the severity of health problems present at diagnoses. This review will focus on the 
genetic influence on the disease, health issues related to both the disease and its 
treatment, and current research on alternative treatment methods.  
 
GENETIC INFLUENCE 
Celiac disease is a genetically susceptible disease. There are several known genes and 
gene combinations that increase an individual’s likelihood of getting the disease. The 
human leukocyte antigen (HLA) complex, a version of the major histocompatibility 
complex (MHC), is a group of proteins that help the immune system differentiate 
between the body’s proteins and foreign proteins.(6) The MHC class II genes are HLA-
DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-DRB1.(6) Thus far the 
HLA-DQA1 and HLA-DQB1 genes have been found to have the strongest effect within 
the MHC region on the development of the disease.(3) Individuals with CD have a 95% 
probability of having a DQA1 gene and a 98% probability of having a DQB1 gene(4). 
These account for about 23% of the heritability risk.(3)  
Each MHC class II gene can have different allele variations and each variation is given a 
specific number.(6) The variants HLA-DQA1*05:01 or HLA-DQA1*05:05 bind to HLA-
DQB1*02:01 or HLA-DQB1*02:02 to form HLA-DQ2, and the variants HLA-DQA1*03:01 
or HLA-DQA1*03:02 bind to HLA-DQB1*03:02 to form HLA-DQ8.(6) Individuals with CD 
have a 93% probability of having a DQ2 gene.(4) In addition, individuals with the HLA 
molecule DQ2.5, an isoform of DQ2, are at a high risk of getting CD(7) and those who are 
homozygous for the haplotype DQ2 are diagnosed at a younger age.(8) Five independent 
variants in the MHC region (not in the HLA-DQ genes) and 57 independent single-
nucleotide polymorphism (SNPs) outside the MHC region are associated with celiac 
disease risk.(3)  
Specifically, the SNP’s rs11100722 and rs4956400 from the interleukin (IL)- 15 gene were 
found to be associated to CD.(9) There is also a connection between the IL15RA 
genotype and if an individual is diagnosed as a child or an adult.(9) Not only do genes 
play a role in the susceptibility of an individual to CD, they also play a role in when the 
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individuals will get the disease. Thus, understanding the genetic background of the 
disease can allow for an earlier diagnosis.   
 
HEALTH ISSUES 
All CD Individuals 
Since gluten exposure in CD damages the villi in their small intestine, they do not always 
get the amount of nutrients they need. Because of this, these individuals compared to 
the general population have an increase in mortality rate with malignancies, vascular 
disease and respiratory disease being the most common cause of death.(10, 11) This 
difference in mortality rate lessens as time from CD diagnosis increases.(10) In addition, 
individuals with CD are generally at a higher risk of getting any lymphoproliferative 
disease and small-intestinal lymphomas.(12) Furthermore, they are at an increased risk 
of myocardial infection, angina pectoris, and stroke even though they do not have the 
typical cardiovascular risk factors.(13) Since they do not have these typical risk factors 
the diagnosis and treatment of these other health problems may prove to be more 
difficult to determine and thus more damage to the body will happen.  
 
Presence vs Absence of Gastrointestinal Symptoms  
Individuals with CD are typically placed into two groups: those with gastrointestinal 
symptoms or those without gastrointestinal symptoms. It is important to study both 
groups as there is a delay in diagnosis between them. Individuals without gastrointestinal 
symptoms have a delay of 42 months from their first doctors visit to their diagnosis from 
biopsy compared to those who have the symptoms who usually have a delay of 2.3 
months.(14) Individuals with thyroid abnormalities, other autoimmune diseases, 
anemia, bone mineral density loss and lower ferritin and cholesterol levels have a higher 
chance of having undiagnosed celiac disease and should be screened for the disease.(14, 
15) These are not symptoms of CD, but they can be associated with the disease. Thus, a 
simple blood analysis for antibodies and/or genetic factors may give an early diagnosis. 
The prolonged exposure to gluten before diagnosis will cause more damage to the body 
than if they had been diagnosed sooner. Thus, individuals who do not have the typical 
gastrointestinal symptoms are more likely to have anemia (69.4% compared to 21.2%), 
low bone mineral density (68% compared to 41%) and abnormal thyroid-stimulating 
hormone (43.2% compared to 15.5%) with hypothyroidism being more common than 
hyperthyroidism.(14) 
 14 
 
 
Gluten Free Diet 
A gluten free diet is the only current treatment for CD, yet 30% of affected individuals 
still have symptoms(16) which can be limiting to the person’s life. A study done in Italy 
on 13-18 year old’s found 30.8% avoided restaurants most or all of the time and 7.9% 
avoided traveling most or all of the time.(17) Either gluten free foods and items need to 
be more prominent and accessible so people do not feel limited or an alternative 
treatment must be created that allowed CD individuals to consume gluten without 
harming themselves. 92.1% brought gluten-free food while traveling(17) because gluten 
free food can be hard to find in some locations. Having this unnecessary stress of where 
and what they can eat and feelings of isolation from missing out can be harmful to the 
individual. In fact, a GFD may cause mental or emotional problems in addition to physical 
problems. A study found that all CD individuals with mucosal healing had a higher risk of 
getting anxiety compared to CD individuals with continuous villous atrophy, and CD 
women with mucosal healing had a higher risk of getting depression compared to CD 
women who had continuous villous atrophy.(18) Their small intestine and therefore 
digestion was improving but avoiding the items with gluten and their vigilance to the 
GFD was mentally harmful.  
 
ALTERNATIVE TREATMENTS 
While a gluten free diet is the only current treatment for celiac disease, it is not always 
the most effective. Certain situations can make it hard for an individual to have access to 
gluten free food, certain foods labeled gluten free may be contaminated,(19) and 
individuals who do not get enough nutrients and minerals from their GFD are at a higher 
risk of health problems.(2) Because of this, many studies are investigating alternative 
treatments. A peptide-based, epitope-specific immunotherapy called Nexvax2 was used 
in a phase 1 study that investigated the effect of varying starting dosages and maximum 
dosages on villus recovery.(20) A starting dose of 3 μg and a maintenance dose of 300 μg 
had the least amount of drug related adverse events with only 20% of those events being 
graded at least moderate to severe(20) (Table 1). This drug is supposed to increase an 
individual’s tolerance of gluten which will eventually allow them to consume gluten again 
without the damage it originally caused. Therefore, it will also lessen health issues 
associated with CD providing better quality of life to affected individuals. Participants 
were separated into two cohorts which may explain differences in effectiveness: cohort 
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1 were those who are homozygous for HLA-DQ2.5 and cohort 2 were those who are non-
homozygous.(20) 
Studying the immune system, specifically the characteristics that the body is having an 
immune response, is important in celiac disease treatments because it proves whether 
the treatment is effective. For instance, the presence of the antibodies anti-
transglutaminase (anti-tTG) and endomysium (EMA) after ingesting gluten means the 
body is having an immune response.  A study found individuals getting microbial 
transglutaminase (mTG) -modified wheat flour are less likely to have positive serum anti-
tTG and EMA antibodies results and less likely to have intestinal villous atrophy because 
there is less or no immune response to gluten.(21) Individuals ingesting the unmodified 
flour had more severe bloating, nausea and abdominal pain and swelling.(21) Therefore, 
the modified flour seems safer than the unmodified, but approximately 25% of the 
individuals consuming modified flour still had disease activity following the trial(21) 
(Table 1). Larger and longer studies with more palatable food should be done to get a 
better understanding on the affect mTG modified wheat flour has on CD individuals.(21) 
Another study is investigating the affect oligofructose-enriched inulin, a type of prebiotic 
referred to as Synergy 1, on intestinal microbiota in children with CD.(22) There were 
only a few episodes of side effects where were fairly equal between the treatment and 
placebo groups.(22) The kids getting Synergy 1 had normal stools more often than the 
children getting the placebo (Table 1) and one child even had alleviation of CD symptoms 
that were present before the trial while taking Synergy 1.(22) 
 
CONCLUSION 
Celiac disease affects 0.5%-1% of the global population putting them at risk for other 
health issues and the only treatment is to avoid the consumption of gluten.(1) This 
treatment is not the most effective as it may be hard for individuals to follow this in 
certain situations, they may ingest contaminated food, they may continue to have 
symptoms, or they may feel isolated.(16, 17, 19) In addition, not everyone has the same 
symptoms,(14) so some people continue eating gluten even though it is damaging their 
intestine. It is important to study this disease because misdiagnoses, no diagnoses, or 
the lack of other treatments can increase chances of certain health problems and 
mortality. In addition, understanding the influence of specific genes on the disease can 
help find better treatments and allow for earlier diagnosis.(9) Additionally, broader 
studies should be done to find specific immunotherapy drugs that improve gluten 
tolerance without causing any adverse events for all individuals with celiac disease. An 
improved tolerance would allow individuals with CD to have more freedom in where and 
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what they eat and where they travel which would improve the affected individual’s 
quality of life. 
 
Table 1: The side effects and effectiveness of potential treatments for celiac disease  
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